Introduction
Glioblastoma Multiforme (GBM) is the most common and devastating form of brain tumour in adults. Following surgery and postoperative radiotherapy median survival is less than 1 year.
Although resection of visible tumour may be possible in up to half of patients, [1] the infiltrative nature of this tumour means complete surgical eradiation is rarely possible. The value of postoperative radiotherapy was unequivocally demonstrated by the Brain Tumour Study Group in 1980 [2] but for the next 25 years there was little or no progress in the treatment of this disease. The lack of new treatments contrasts with the very substantial progress seen in the treatments of other cancers, particularly breast cancer, [3] during this time period. In 2002 [4] a meta-analysis of 12 trials of either adjuvant, neoadjuvant or concomitant chemotherapy plus radiotherapy showed a modest but significant survival increase when chemotherapy was combined with radiotherapy. The most common agent used was lomustine. This study showed a significant prolongation in survival associated with chemotherapy with a hazard ratio of 0.85 (95% CI 0.78 to 0.91 p = <0.001). This was equivalent to a 2 month's increase in median survival time. The authors' conclusion was the small but clear improvement in survival from chemotherapy encouraged further studies of drug treatment for these tumours.
The most influential study was carried out by the European Organisation for Research and Treatment of Cancer (EORTC) and the National Cancer Institute of Canada (NCIC) [1] . This was a randomised trial of treatment of GMB by radiotherapy alone compared with radiotherapy plus concomitant and adjuvant temozolomide (TMZ). TMZ is an oral alkylating agent which previously has been shown to have significant activity when used to treat recurrent high grade glioma [5] . In the EORTC/NCIC trial 573 patients were randomised either to radiotherapy alone This trial showed a significant advantage for the combination of radiation and TMZ compared to radiation alone. At a median follow-up of 28 months the median survival was 14.6 months with radiation and TMZ and 12.1 months for radiation alone. The two year survival rate was 26.5%
with radiation plus TMZ versus 10.4% with radiation alone.
Although the trial design did not allow a distinction between the relative contribution of the concomitant and maintenance components of the schedule, information in the study and in a paper published simultaneously [6] suggested that the concomitant phase was the most important. Benefit from TMZ seems to be restricted to patients suffering from a GBM with epigenetic silencing of the methylguanine methyl transferase gene (MGMT) by methylation following TMZ treatment. MGMT is a DNA repair enzyme and is a cause of resistance both to alkylating agents and radiation therapy [7] . In total 45% of 206 assessable cases were shown to have epigenetic silencing of the MGMT gene using methylation specific polymerase chain reaction analysis. Clinical benefit was restricted to this group of patients and was not seen in However as the concomitant part of the schedule seemed to be the most important component, the hospital cancer directorate agreed to fund concomitant TMZ (but not the adjuvant cycles).
The money was found from existing resources. As the treatment we could offer patients was significantly different from the full EORTC schedule, we planned to audit the results of this policy. This retrospective study examines the results of treatment of GBM patients treated by concomitant TMZ and radical radiotherapy. In those with less extensive disease, received a tumour dose of 60 Gy in 30 fractions given over 6-weeks using 6mV X-rays. The volume irradiated was the contrast enhanced tumour volume plus a 3 cm margin of apparently uninvolved brain. All patients began radiotherapy within 6
weeks of surgery or biopsy if inoperable. TMZ was given at a dose of 75mg/m 2 by mouth starting on the first day of radiotherapy and ending on the last day of therapy. The antiemetic metoclopramide was prescribed at 10mg three times a day. Patients were reviewed along with the previous day's full blood count and serum biochemistry at least once a week during chemo radiation therapy, and toxicity was recorded using the common toxicity scale.
Overall survival (OS) was calculated from the date chemo radiation started to the date of death.
For those patients still alive, their OS was censored at the date they were last known to be alive.
Kaplan-Meier estimates of OS survival curves, median survival times and 95% confidence intervals were obtained [8] . The hazard ratio for comparing between the extent of disease groups was estimated using Cox proportional hazards regression [8] . (Table 1) . It is noteworthy that 21 (91%) of the less extensive were treated by debulking surgery, while for those with extensive disease more than half (58%) had biopsy only mainly due to their large, multicentric disease.
The combined treatment was remarkably well tolerated with 85% of patients showing no evidence of toxicity. No patients suffered nausea and vomiting, perhaps in part due to prophylactic metoclopramide and concomitant steroid administration. Two patients had raised liver transaminases (raised ALT), grade 2 and 3 respectively. This was more likely due to anticonvulsant medication than TMZ. Haematological toxicity was confined to two patients one who developed grade 2 thrombocytopenia which led to a dose reduction. The second patient (who had very extensive tumour) had grade IV thrombocytopenia. This was of sudden onset and the TMZ was discontinued immediately. Five weeks elapsed before the plate count returned to >100 and during this time period the patient developed a grade III anaemia requiring transfusion.
Of the 35 patients treated, 5 remain alive all with the less extensive disease at diagnosis (Table   1 ). Amongst those with very extensive disease the median survival time is 3.8 months (95% CI 0.7 to 8.1) none are alive beyond 13.8 months. For those with less extensive disease the median is 17.1 months (11.5 to 18.6) with an estimated proportion alive beyond 2 years of 18%.
The survival curves are shown in Fig 1 and the hazard ratio reflecting the relatively poorer outcome in those with very extensive disease is 7.4 (95% CI 2.9 to 18.1, p <0.001).
Discussion
The survival of patients with very large or multi-centric GBM often with a poor performance status was poor with a median survival of only 3. 
Conflict of interest statement
None of the authors have any conflict of interest. Time from diagnosis (years) 9 
